Literature DB >> 1913703

Dopa-responsive dystonia masquerading as idiopathic kyphoscoliosis.

F Micheli1, M F Pardal, E Gatto, G Paradiso.   

Abstract

A 19-year-old girl with a long-standing history of kyphoscoliosis misdiagnosed as idiopathic was offered corrective surgery on several occasions but fortunately refused, since neurological examination later found evidence of mild dystonic posturing in the neck and right leg. Symptoms worsened toward evening but improved with rest. Treatment with low doses of levodopa led to total remission within a month. Our case illustrates that dopa-responsive dystonia can manifest spinal curvature as the major symptom and warrants its inclusion in the differential diagnoses of idiopathic kyphoscoliosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913703     DOI: 10.1097/00002826-199108000-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  Abnormal activation of the motor cortical network in idiopathic scoliosis demonstrated by functional MRI.

Authors:  Julio Domenech; G García-Martí; L Martí-Bonmatí; C Barrios; J M Tormos; A Pascual-Leone
Journal:  Eur Spine J       Date:  2011-04-16       Impact factor: 3.134

2.  Familial adolescent-onset scoliosis and later segmental dystonia in an Irish family.

Authors:  Sean O'Riordan; Timothy Lynch; Michael Hutchinson
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

3.  Rare causes of scoliosis and spine deformity: experience and particular features.

Authors:  Konstantinos C Soultanis; Alexandros H Payatakes; Vasilios T Chouliaras; Georgios C Mandellos; Nikolaos E Pyrovolou; Fani M Pliarchopoulou; Panayotis N Soucacos
Journal:  Scoliosis       Date:  2007-10-23

4.  Motor cortical hyperexcitability in idiopathic scoliosis: could focal dystonia be a subclinical etiological factor?

Authors:  Julio Doménech; José María Tormos; Carlos Barrios; Alvaro Pascual-Leone
Journal:  Eur Spine J       Date:  2009-12-24       Impact factor: 3.134

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.